Compare Stocks: ZFGN, DBVT, ANNX, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.64 +6.0%	$5.81	$1.74 ▼ $6.60	$788.61M	0.79	1.97 million shs	5.84 million shs
ANNX Annexon	$3.95 +0.3%	$5.26	$2.32 ▼ $7.18	$748.84M	1.21	2.92 million shs	2.90 million shs
DBVT DBV Technologies	$12.35 +4.2%	$14.22	$8.85 ▼ $26.18	$776.54M	-0.95	304,876 shs	269,583 shs
ZFGN Zafgen	$5.09 +1.0%	$18.47	$0.62 ▼ $2.76	$190.72M	0.27	360,199 shs	1.32 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-13.78%	-7.96%	+22.02%	+172.82%
ANNX Annexon	0.00%	-19.10%	-25.52%	-15.09%	+62.81%
DBVT DBV Technologies	0.00%	-12.03%	-15.48%	-34.60%	+20.06%
ZFGN Zafgen	0.00%	0.00%	0.00%	0.00%	+29.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.64 +6.0%	$5.81	$1.74 ▼ $6.60	$788.61M	0.79	1.97 million shs	5.84 million shs
ANNX Annexon	$3.95 +0.3%	$5.26	$2.32 ▼ $7.18	$748.84M	1.21	2.92 million shs	2.90 million shs
DBVT DBV Technologies	$12.35 +4.2%	$14.22	$8.85 ▼ $26.18	$776.54M	-0.95	304,876 shs	269,583 shs
ZFGN Zafgen	$5.09 +1.0%	$18.47	$0.62 ▼ $2.76	$190.72M	0.27	360,199 shs	1.32 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-13.78%	-7.96%	+22.02%	+172.82%
ANNX Annexon	0.00%	-19.10%	-25.52%	-15.09%	+62.81%
DBVT DBV Technologies	0.00%	-12.03%	-15.48%	-34.60%	+20.06%
ZFGN Zafgen	0.00%	0.00%	0.00%	0.00%	+29.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	100.95% Upside
ANNX Annexon	2.40	Hold	$15.14	283.36% Upside
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	292.71% Upside
ZFGN Zafgen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZFGN, DBVT, ANNX, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
7/21/2026	ANNX Annexon	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform
7/21/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform	$3.00
7/20/2026	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
7/17/2026	ANNX Annexon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $25.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$8.22M	95.95	N/A	N/A	$0.85 per share	6.64
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$4.20 per share	N/A
ZFGN Zafgen	N/A	N/A	N/A	N/A	$1.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
ZFGN Zafgen	-$45.41M	-$1.07	N/A	N/A	N/A	N/A	-51.34%	-34.55%	N/A

Latest ZFGN, DBVT, ANNX, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
ZFGN Zafgen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
ANNX Annexon	N/A	5.53	5.53
DBVT DBV Technologies	N/A	3.72	3.72
ZFGN Zafgen	0.26	6.56	6.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
ANNX Annexon	N/A
DBVT DBV Technologies	71.74%
ZFGN Zafgen	70.43%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
ANNX Annexon	10.31%
DBVT DBV Technologies	1.06%
ZFGN Zafgen	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
ZFGN Zafgen	38	37.47 million	N/A	Not Optionable

ZFGN, DBVT, ANNX, and ACRS Headlines

Recent News About These Companies

GSK/Sirtris compounds dogged by assay artifacts

May 21, 2024 | nature.comN

Tokyo Steel Manufacturing Co Ltd 5423

May 16, 2024 | morningstar.comM

Diagnosing Diabetes: Not So Simple

November 2, 2023 | medscape.comM

Do New Weight Loss Meds Mean the End of Bariatric Surgery?

October 6, 2023 | medscape.comM

Prader-Willi syndrome

August 23, 2023 | pharmaphorum.comP

The Omnipod 5 System: Trial Results From ENDO 2021

August 4, 2023 | medscape.comM

Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?

July 5, 2023 | medscape.comM

Oral Semaglutide Brings GLP-1s to Primary Care

May 20, 2023 | medscape.comM

Clinical Trials - Different Phases of the trial News, Research and Latest Updates

May 20, 2023 | medindia.netM

Obesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journal

May 12, 2023 | news.google.comN

Weight Loss and Obesity Management Market Insights With ... - Taiwan News

May 11, 2023 | news.google.comN

Global Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examiner

May 4, 2023 | news.google.comN

Weight Loss and Obesity Management Market May See a Big Move ... - Digital Journal

May 2, 2023 | news.google.comN

Ironwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocks

May 2, 2023 | news.google.comN

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation

April 29, 2023 | medscape.comM

Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Reference

April 21, 2023 | news.google.comN

Anti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journal

April 20, 2023 | news.google.comN

Anti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPR

April 14, 2023 | news.google.comN

New ADA Standards: Promoting Health

April 13, 2023 | medscape.comM

New ADA Standards: Promoting Health

April 13, 2023 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZFGN, DBVT, ANNX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.64 +0.32 (+6.02%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 -0.14 (-2.48%)

As of 07:30 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Annexon NASDAQ:ANNX

$3.95 +0.01 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.94 -0.02 (-0.38%)

As of 07:30 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

DBV Technologies NASDAQ:DBVT

$12.35 +0.50 (+4.22%)

Closing price 04:00 PM Eastern

Extended Trading

$12.34 -0.01 (-0.08%)

As of 04:40 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Zafgen NASDAQ:ZFGN

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZFGN, DBVT, ANNX, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZFGN, DBVT, ANNX, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZFGN, DBVT, ANNX, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZFGN, DBVT, ANNX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Annexon NASDAQ:ANNX

DBV Technologies NASDAQ:DBVT

Zafgen NASDAQ:ZFGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZFGN, DBVT, ANNX, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZFGN, DBVT, ANNX, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZFGN, DBVT, ANNX, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZFGN, DBVT, ANNX, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Annexon NASDAQ:ANNX

DBV Technologies NASDAQ:DBVT

Zafgen NASDAQ:ZFGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools